My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 176

    1.

    Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein E?

    Dallinga-Thie GM, van Tol A, Hattori H, Rensen PC, Sijbrands EJ.

    Diabetes. 2006 May;55(5):1491-6.PMID: 16644710 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Plasma pre beta-HDL formation is decreased by atorvastatin treatment in type 2 diabetes mellitus: Role of phospholipid transfer protein.

    Dallinga-Thie GM, van Tol A, Dullaart RP; Diabetes Atorvastatin lipid intervention (DALI) study group.

    Biochim Biophys Acta. 2009 Aug;1791(8):714-8. Epub 2009 Mar 19.PMID: 19303940 [PubMed - indexed for MEDLINE]Related articles

    3.

    Plasma apolipoprotein A5 and triglycerides in type 2 diabetes.

    Dallinga-Thie GM, van Tol A, Hattori H, van Vark-van der Zee LC, Jansen H, Sijbrands EJ; DALI study group.

    Diabetologia. 2006 Jul;49(7):1505-11. Epub 2006 Apr 28.PMID: 16752169 [PubMed - indexed for MEDLINE]Related articles

    4.

    Influence of atorvastatin on apolipoprotein E and AI kinetics in patients with type 2 diabetes.

    Bach-Ngohou K, Ouguerram K, Frénais R, Maugère P, Ripolles-Piquer B, Zaïr Y, Krempf M, Bard JM.

    J Pharmacol Exp Ther. 2005 Oct;315(1):363-9. Epub 2005 Jul 13.PMID: 16014756 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Role of plasma adiponectin on the HDL-cholesterol raising effect of atorvastatin in patients with type 2 diabetes.

    van Hoek M, van Tol A, van Vark-van der Zee LC, Jansen H, Kastelein JJ, Sijbrands EJ, Dallinga-Thie GM.

    Curr Med Res Opin. 2009 Jan;25(1):93-101.PMID: 19210142 [PubMed - indexed for MEDLINE]Related articles

    6.

    Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes.

    van Venrooij FV, Stolk RP, Banga JD, Sijmonsma TP, van Tol A, Erkelens DW, Dallinga-Thie GM; DALI Study Group.

    Diabetes Care. 2003 Apr;26(4):1216-23.PMID: 12663600 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides.

    Dallinga-Thie GM, Berk-Planken II, Bootsma AH, Jansen H; Diabetes Atorvastatin Lipid intervention (DALI) Study Group.

    Diabetes Care. 2004 Jun;27(6):1358-64.PMID: 15161788 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Plasma apolipoprotein E concentration is an important determinant of phospholipid transfer protein activity in type 2 diabetes mellitus.

    Tan KC, Shiu SW, Wong Y, Wong WK, Tam S.

    Diabetes Metab Res Rev. 2006 Jul-Aug;22(4):307-12.PMID: 16389649 [PubMed - indexed for MEDLINE]Related articles

    9.

    Type 2 diabetes mellitus is associated with differential effects on plasma cholesteryl ester transfer protein and phospholipid transfer protein activities and concentrations.

    Dullaart RP, De Vries R, Scheek L, Borggreve SE, Van Gent T, Dallinga-Thie GM, Ito M, Nagano M, Sluiter WJ, Hattori H, Van Tol A.

    Scand J Clin Lab Invest. 2004;64(3):205-15.PMID: 15222630 [PubMed - indexed for MEDLINE]Related articles

    10.

    Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.

    Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J, Browne P.

    Acta Neurol Scand Suppl. 2006;185:3-7.PMID: 16866904 [PubMed - indexed for MEDLINE]Related articles

    11.

    The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.

    Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Cariolou M, Ganotakis ES, Mikhailidis DP, Elisaf MS.

    J Cardiovasc Pharmacol Ther. 2006 Sep;11(3):211-21.PMID: 17056835 [PubMed - indexed for MEDLINE]Related articles

    12.

    Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study.

    Usharani P, Mateen AA, Naidu MU, Raju YS, Chandra N.

    Drugs R D. 2008;9(4):243-50.PMID: 18588355 [PubMed - indexed for MEDLINE]Related articles

    13.

    Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).

    Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone SJ, Neil HA, Newman CB, Szarek M, DeMicco DA, Durrington PN.

    Diabetologia. 2009 Feb;52(2):218-25. Epub 2008 Oct 30. Erratum in: Diabetologia. 2009 Mar;52(3):556. PMID: 18972097 [PubMed - indexed for MEDLINE]Related articles

    14.

    Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein.

    Settasatian N, Barter PJ, Rye KA.

    J Lipid Res. 2008 Jan;49(1):115-26. Epub 2007 Oct 5.PMID: 17921435 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Statins of different brain penetrability differentially affect CSF PLTP activity.

    Vuletic S, Riekse RG, Marcovina SM, Peskind ER, Hazzard WR, Albers JJ.

    Dement Geriatr Cogn Disord. 2006;22(5-6):392-8. Epub 2006 Sep 7.PMID: 16960448 [PubMed - indexed for MEDLINE]Related articles

    16.

    Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria.

    Dogra GK, Watts GF, Chan DC, Stanton K.

    Diabet Med. 2005 Mar;22(3):239-42.PMID: 15717868 [PubMed - indexed for MEDLINE]Related articles

    17.

    Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro.

    Vuletic S, Peskind ER, Marcovina SM, Quinn JF, Cheung MC, Kennedy H, Kaye JA, Jin LW, Albers JJ.

    J Neurosci Res. 2005 May 1;80(3):406-13.PMID: 15795933 [PubMed - indexed for MEDLINE]Related articles

    18.

    Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.

    Betteridge DJ, Gibson JM.

    Diabet Med. 2007 May;24(5):541-9. Epub 2007 Mar 15.PMID: 17367312 [PubMed - indexed for MEDLINE]Related articles

    19.

    A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.

    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.

    Clin Ther. 2008 Jun;30(6):1089-101.PMID: 18640465 [PubMed - indexed for MEDLINE]Related articles

    20.

    Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.

    Hogue JC, Lamarche B, Deshaies Y, Tremblay AJ, Bergeron J, Gagné C, Couture P.

    Metabolism. 2008 Feb;57(2):246-54.PMID: 18191056 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity